Z01 BC 010585 (Z01) | |||
---|---|---|---|
Title | A Phase I Trial of CC-5013 (lenalidomide) in Pediatric Patients with Recurrent or | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Warren, Katherine | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $17,049 | Project Dates | 10/01/2004 - N/A |
Fiscal Year | 2007 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Neurosciences Research (100.0%) | Nervous System (100.0%) | ||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
The study has accrued quickly and is ongoing. We are currently evaluating a dose of lenalidomide that is >2x the typical adult dose and have not seen significant toxicity in our study population. We have observed at least 7 patients with long-term stable disease (>6 months) which is significant in a Phase I study. There are plans and letters of intent to further develop this agent and test efficacy in a Phase II study within the Children's Oncology Group and in combination trials within NCI. |